Skip to main content

Table 1 Baseline characteristics of 268 ICI patients receiving antifungal therapy in the China-SCAN study

From: Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study

Variables Empirical
N = 142
Pre-emptive
N = 53
Targeted
N = 73
P-value
Age, years 58.3 ± 21.6 58.3 ± 18.4 68.7 ± 16.2 0.001
Gender, n (%)     0.414
 Male 98 (69.0) 40 (75.5) 47 (64.4)  
 Female 44 (31.0) 13 (24.5) 26 (35.6)  
Body weight, kg 61.8 ± 10.7 63.5 ± 10.4 63.8 ± 10.1 0.473
Hospital stays before ICU admission, days 0.5 (10.0) 1.0 (4.5) 0.0 (11.5) 0.829
ICU stays before candidiasis onset, days 9.0 (17.0) 10.0 (14.5) 11.0 (33.0) 0.717
Hospital stays before candidiasis onset, days 16.5 (23.3) 12.0 (24.5) 16.0 (41.0) 0.461
Underlying disease, n (%)
 Diabetic mellitus 28 (19.7) 13 (24.5) 21 (28.8) 0.318
 Chronic cardiac dysfunctiona 23 (16.2) 14 (26.4) 17 (23.3) 0.210
 Chronic obstructive pulmonary disease 15 (10.6) 6 (11.3) 12 (16.4) 0.449
 Chronic renal insufficiencyb 12 (8.5) 5 (9.4) 13 (17.8) 0.108
 Chronic hepatic insufficiencyc 4 (2.8) 1 (1.9) 6 (8.2) 0.111
 Solid tumor 26 (18.3) 7 (13.2) 17 (23.3) 0.353
 Haematological malignancy 2 (1.4) 1 (1.9) - 0.545
Illness severity at ICU admission
 APACHE II score 20.0 ± 9.2 20.9 ± 8.1 21.5 ± 8.6 0.517
 SOFA score 7.2 ± 3.7 7.7 ± 3.4 6.8 ± 3.8 0.434
  1. Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)
  2. APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment
  3. aAll patients corresponding to the New York Heart Association (NYHA) standards of level II or higher
  4. bAll patients receiving long-term hemodialysis
  5. cAs described according to APACHE II criteria: biopsy-proven cirrhosis and documented portal hypertension; episodes of past upper gastrointestinal bleeding attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma